Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – October 30, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today ...